ArticleScientific reports2025
Emotional state in patients after COVID-19 in relation to comprehensive rehabilitation, Brain-Derived neurotrophic factor, Irisin levels, and selected clinical factors.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The outbreak of the COVID-19 epidemic is a breach of health protection worldwide. Complications in people who limit the risk of COVID-19 can be associated with physical and mental health. Identification of states associated with anxiety and depression and threats that may occur in patients after COVID-19 is a very important aspect that occurs on the selection of therapeutic methods, and thus recovery occurs. The aim of the study was to assess the penalty in the treatment of anxiety symptoms and depressiveness in a patient after COVID-19. The study includes the effects resulting from brain-derived neurotrophic factor, irisin and other problems related to problems and depressive symptoms in patients after COVID-19. included in the study participation in the rehabilitation education program in stationary conditions. The Generalized Anxiety Disorder Questionnaire was used to solve anxiety problems. The Beck Depression Inventory was used to assess the effects of depression. To assess the update of the irisin (ng/mL) and brain-derived neurotrophic factor (ng/mL) configuration on the day of treatment initiation from each patient's blood was collected from a female venous sample. After rehabilitation, patients scored lower in both depression and anxiety assessments. Women had higher scores in the assessment of anxiety disorders and depression. The longer the period from the end of COVID-19 treatment to the start of rehabilitation, the higher the Generalized Anxiety Disorder Questionnaire and The Beck Depression Inventory scores. The higher the Generalized Anxiety Disorder Questionnaire and The Beck Depression Inventory scores, the lower the handgrip strength values. With increasing irisin concentration, The Beck Depression Inventory values also increased. Comprehensive rehabilitation may be associated with a reduction in the severity of anxiety and depressive symptoms in patients after COVID-19. Earlier initiation of rehabilitation may be associated with better emotional well-being in patients after COVID-19. The severity of anxiety and depressive symptoms may be associated with gender, age, and hospitalization during COVID-19 treatment. Increased irisin levels in patients after COVID-19 may be associated with inflammatory and metabolic complications after infection. However, interpretation of these relationships requires further studies taking into account additional biological variables and prospective analyses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.